Showing results (131-140 of 217) with videos related to
Sort By:
Pageof 22
Plos One|September 28, 2011
Secreted protein acidic and rich in cysteine is a matrix scavenger chaperoneAlexandre Chlenski, Lisa J Guerrero, Helen R Salwen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk StratificationHannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.Clinical and Translational Science|February 22, 2026
Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in NeuroblastomaGepoliano S Chaves, Mohansrinivas Chennakesavalu, Kelley Moore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectWendy B London, Victoria Castel, Tom Monclair, et al.Molecular Cancer Therapeutics|January 25, 2019
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for NeuroblastomaAlexandre Chlenski, Chanyoung Park, Marija Dobratic, et al.Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.The Lancet. Child & Adolescent Health|January 30, 2018
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trialPedro A de Alarcon, Katherine K Matthay, Wendy B London, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.Cell Reports|May 20, 2014
TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastomaChristopher J Mariani, Aparna Vasanthakumar, Jozef Madzo, et al.Pageof 22